RecruitingPhase 2NCT07216027

A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema

A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-08049820 IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS


Sponsor

Pfizer

Enrollment

165 participants

Start Date

Nov 20, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of this study is to learn if the study medicine (PF-08049820) is safe and effective for the treatment of atopic dermatitis (AD), also known as eczema, or atopic eczema. People with this condition may have severe itching and rashes on the skin. The study is seeking participants who: 1. Are aged 18 years or older; 2. Were confirmed to have AD at least 6 months ago; 3. Do not have a suitable prescribed medicine for AD; 4. Are considered by their doctors to have moderate to severe AD. The study has two stages (Stage 1 and Stage 2). In both stages, eligible participants will take either PF-08049820 or placebo as tablets by mouth daily for 12 weeks. A placebo does not have any medicine in it but looks just like the medicine being studied. Participants will visit the clinic on Day 1, Weeks 1, 2, 4, 6, 8 and 12. They will have a follow-up visit at Week 16. During this time, the participant's health and skin condition will be checked. They will have blood and urine tests. They will also have to answer questions about their health, skin condition, and how much their skin condition affects their lives. The experiences of participants receiving the study medicine will be compared to those receiving placebo. This will help to understand if PF-08049820 is safe and effective.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called PF-08049820 and a drug called Placebo for people with atopic dermatitis and eczema, atopic. The study is currently recruiting participants at 10 locations.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGPF-08049820

Tablet

DRUGPlacebo

Tablet


Locations(10)

Northridge Clinical Trials

Northridge, California, United States

Clinical Science Institute

Santa Monica, California, United States

Gsi Clinical Research

Margate, Florida, United States

Skin Research of South Florida

Miami, Florida, United States

Hattori Dermatology Clinic

Takasaki, Gunma, Japan

Kosugi Dermatology Clinic

Kawasaki-shi, Kanagawa, Japan

Queen's Square Medical Facilities

Yokohama, Kanagawa, Japan

Dermatology and Ophthalmology Kume Clinic

Sakai, Osaka, Japan

Nihonbashi Sakura Clinic

Chuo-ku, Tokyo, Japan

Fukuwa Clinic

Chuo-ku, Tokyo, Japan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07216027


Related Trials